Changing the landscape of European School of Oncology–European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic

Nicholas Pavlidis*1,2, Fedro A Peccatori3,4, Alexandru Eniu2,5, Elie Rassy6, Matti Aapro7, Franco Cavalli8, Florian Lordick9 & Alberto Costa3

1University of Ioannina, Ioannina, Greece
2European School of Oncology College (ESCO), Milan, 20121, Italy
3European School of Oncology (ESO), Milan, 20121, Italy
4Gynecologic Oncology Department, European Institute of Oncology IRCCS, Milan, 20141, Italy
5Hospital Riviera Chablais, Rennaz, 1847, Switzerland
6Gustave Roussy, Département de Médecine Oncologique, Villejuif, 94805, France
7Breast Center, Genolier Cancer Centre, Genolier, 1272, Switzerland
8Oncology Institute of Southern Switzerland, Bellinzona, 6500, Switzerland
9University of Leipzig Medical Centre, University Cancer Center (UCCL), Leipzig, 04103, Germany
*Author for correspondence: npavlid@uoi.gr

Aims: This study aimed to assess the participants’ evaluation of the European School of Oncology–European Society for Medical Oncology virtual masterclasses in clinical oncology (MCOs) organized during the pandemic in 2021. Materials & methods: The participants answered an online evaluation questionnaire at the end of each MCO to evaluate the content and organization of the MCO. Results: The clinical session and case presentation scores ranged between 4.6 and 4.8 over 5. The participants strongly agreed that the MCOs offered updates to improve their knowledge and practice in 68–83% and 52–76%, respectively; 74–90% of the participants considered the quality of the meetings to be excellent. Conclusion: The participants were satisfied with the virtual MCOs during the COVID-19 pandemic. Virtual MCO may be an acceptable alternative educational modality in specific circumstances.

Plain language summary: In 2002, the European School of Oncology (ESO) established masterclasses in clinical oncology (MCOs) and provided 41 in-person courses over the past two decades. As the COVID-19 pandemic forced travel restrictions and social distancing, the ESO and the European Society for Medical Oncology (ESMO) adapted the traditional MCOs to create virtual MCOs presented on e-ESO, an ESO e-learning platform. To date, five virtual MCOs have been organized for oncologists from western Europe, Latin America, Arab countries and southern Europe, the Baltic and Eurasia, eastern Europe and the Balkans. This study aimed to assess the participants’ evaluation of the ESO-ESMO virtual MCOs organized during the pandemic in 2021 and to compare the participants’ evaluation with that of previous in-person MCOs conducted between 2002 and 2019.

First draft submitted: 17 November 2021; Accepted for publication: 7 June 2022; Published online: 20 June 2022

Keywords: COVID-19 • education • in-person • oncology • teaching • virtual

The far-reaching consequences of the COVID-19 pandemic have led to considerable changes in medical educational programs [1–4]. COVID-19 dismantled healthcare systems worldwide and led to significant anxiety and burnout among many oncologists [5]. As cases were growing worldwide, several healthcare systems redeployed oncologists, as well as the members of other specialties, to the frontline, thus disrupting training programs and face-to-face training [6,7]. The European Society for Medical Oncology (ESMO) has produced a collection of recommendations to guide the management of patients with cancer during the pandemic and supported the well-being of oncology
professionals [8]. However, cancer education of young fellows and oncologists seemed to be overlooked during the pandemic, with many cancer educational events being canceled, interrupted or delayed [9].

The European School of Oncology (ESO) and ESMO masterclasses in clinical oncology (MCOs) are full, 5-day, interactive educational courses designed to enhance participants’ knowledge and skills in medical oncology [10]. During an MCO, the ESO and ESMO faculty experts present in-person lectures that cover the latest diagnostic and treatment updates in oncology. Since 2002, ESO and ESMO have organized in-person MCOs in five different geographic regions yearly. The authors have previously reported the positive impact of ESO-ESMO MCOs on self-professional development, as 95% of the participants in MCOs considered this meeting useful for their professional career [11]. Before the pandemic, young oncologists attended the MCOs in person and commonly reported a high level of satisfaction with the goal, content and organization of the meetings [12,13]. Due to travel restrictions related to the COVID-19 pandemic, ESO canceled the MCO in 2020 and transitioned to a virtual environment in 2021 via e-ESO, an ESO e-learning platform. The authors conducted a survey to assess the participants’ evaluation of the five ESO-ESMO virtual MCOs organized during the pandemic and compared the participants’ evaluation with the previous in-person MCOs conducted between 2002 and 2019.

Materials & methods
Virtual MCO description
The virtual MCOs were teaching courses designed for medical and clinical oncologists to discuss patient management by cancer site and the latest updates. As in in-person meetings, eligible participants were selected on a competitive basis according to their curriculum vitae by a panel of ESO and ESMO experts. Participants and lecturers were emailed an access link prior to the scheduled lecture to provide instructions on navigating the online conferencing platform. The virtual MCO consisted of 13 hours of pre-recorded educational lectures and a 2-day live, online educational event that focused on specific topics of interest for oncologists. The pre-recorded lectures were made available to the participants 1 month before the live, online event. Participants attended these courses and answered three evaluation questions related to each session. During the live, online event, each lecture was followed by a question-and-answer (Q&A) session using some of the questions that were mentioned in the pre-recorded sessions. After each session, the panel of experts discussed the latest updates and solicited questions from the participants for approximately 10 min. Prior to the meeting, participants had to work in pairs to prepare clinical cases, which were presented and discussed with the faculty members during the live, online event [14]. ESO opted for this activity to increase networking among attendees, given that this opportunity is often missing from online educational activities. At the end of the MCO, participants were required to complete a self-assessment test [15].

Evaluation of the MCOs
Participants were asked about their experiences with the virtual MCO using an online evaluation questionnaire that was addressed by an email invitation. Only one reminder email was sent thereafter; the reminder was not personalized and encouraged participants to answer the survey by offering the possibility to join the College of the European School of Oncology [16]. Responses were anonymous and could not be linked to the participant’s score on the final self-assessment test.

A questionnaire of five sections was developed by the ESO faculty at the inception of the in-person MCO and was approved by the ESO ethics board [15]. The first section consisted of four demographic questions. In the second section, three items evaluated whether the MCO improved the participants’ knowledge of and skills in the best clinical practice and ranked the quality of the education offered during the virtual MCO. The third and fourth sections covered the content and organization of the MCO in four and three items, respectively. The last section evaluated the presentations separately according to the slides’ reliability, English quality and general feedback. Responses were collected using Likert scales: strongly agree, agree, neutral, disagree and strongly disagree or excellent, good, fair, poor and very poor. At the end of each section, freehand text answers were allowed to suggest areas of improvement.

Results
Of the 281 participants in the five ESO-ESMO MCOs, 200 (71%) completed the survey. 65% of the participants were female. The majority of the participants were medical or clinical oncologists (n = 119 [69.5%] and 59 [29.5%], respectively; Table 1). The participants were of 56 nationalities and originated mainly from Portugal (n = 22; 11%),...
Table 1. Demographics of the selected participants in the masterclasses in clinical oncology.

|                      | Western Europe | Latin America | Arab countries and southern Europe | Baltic and Eurasia | Eastern Europe and Balkans |
|----------------------|----------------|---------------|-------------------------------------|--------------------|-----------------------------|
| Participants (n)     | 59             | 42            | 32                                  | 36                 | 31                          |
| Age                  |                |               |                                     |                    |                             |
| <35 years            | 38 (64.4%)     | 27 (64.3%)    | 23 (71.9%)                          | 32 (88.9%)         | 25 (80.6%)                  |
| 35–45 years          | 18 (30.5%)     | 15 (35.7%)    | 9 (28.1%)                           | 4 (11.1%)          | 6 (19.4%)                   |
| >45 years            | 3 (5.1%)       |               |                                     |                    |                             |
| Gender               |                |               |                                     |                    |                             |
| Female               | 46 (78.0%)     | 20 (47.6%)    | 24 (75.0%)                          | 23 (63.9%)         | 22 (71.0%)                  |
| Male                 | 13 (22.0%)     | 22 (52.3%)    | 8 (25.0%)                           | 13 (36.1%)         | 9 (29.0%)                   |
| Specialty            |                |               |                                     |                    |                             |
| MO                   | 37 (62.7%)     | 29 (69.0%)    | 11 (34.4%)                          | 23 (63.9%)         | 19 (61.3%)                  |
| CO                   | 16 (27.1%)     | 13 (31.0%)    | 12 (37.5%)                          | 10 (27.8%)         | 8 (25.8%)                   |
| RO                   | 0 (0%)         | 0 (0%)        | 8 (25.0%)                           | 2 (5.6%)           | 3 (9.7%)                    |
| HO                   | 2 (3.4%)       | 0 (0%)        | 1 (3.1%)                            | 0 (0%)             | 0 (0%)                      |
| NM                   | 2 (3.4%)       | 0 (0%)        | 0 (0%)                              | 0 (0%)             | 0 (0%)                      |
| Other                | 2 (3.4%)       | 0 (0%)        | 0 (0%)                              | 1 (2.8%)           | 1 (3.2%)                    |

CO: Clinical oncology; HO: Hematology oncology; MO: Medical oncology; NM: Nuclear medicine; RO: Radiotherapy oncology.

the Russian Federation (n = 20; 10%), Italy (n = 15; 7.5%), Egypt (n = 14; 7%) and Mexico (n = 12; 6%; Table 2).

Regarding the evaluation scores of the clinical sessions and clinical case presentations, the overall scores ranged between 4.6 and 4.8 over 5 in the different geographic regions; the lowest score was in the Arab countries and southern Europe MCO (Table 3). Most of the clinical sessions evaluated by the participants, as well as the clinical case presentations presented by the participants, were highly valued, with an overall scoring of 4.5–4.9 and 4.7–4.9, respectively.

The participants strongly agreed that the MCO offered updates to improve their knowledge in the field and practice in 68–83% and 52–76%, respectively; 74–90% of the participants considered the quality of the meeting to be excellent. The Arab countries and southern Europe MCO participants reported the lowest satisfaction score (Table 4). Among the participants in MCOs, the content of the sessions was well balanced and supported with evidence in 58–77% and the time of the discussion sessions was satisfying in 52–68%. In the evaluation of the event organization, 81–89% of the participants considered the organization and management of the meeting to be excellent, albeit a lower satisfaction with the platform, ranging between 68 and 84%.

The Supplementary Material details the answers provided in the freehand text items intended to suggest areas of improvement. Overall, participants were satisfied with the content and organization. The main suggested area of improvement was relevant to the time of interaction for discussion and questions between the faculty and the participants.

Discussion

The COVID-19 pandemic led to an unprecedented cancelation of the ESO-ESMO MCOs during 2020, rather than an abrupt transition to a virtual teaching environment to deliver didactic lectures during an exhausting period. Nevertheless, the authors primary objectives were in line with the Accreditation Council for Graduate Medical Education (ACGME) and considered that training and teaching programs must continue to provide adequate resources, training and supervision [17]. As previously mentioned, ESMO had already published a series of guidelines for the management of patients during the pandemic. Thereafter, ESO designed e-ESO, a dedicated platform suitable for the MCO lectures and interactions.

This survey aimed to assess the first virtual MCO experience for participants by assessing their satisfaction in regard to the goals, content and organization of the masterclasses. Overall, the results reflect that the majority of the participants were satisfied with the MCOs despite the transition from the traditional in-person to virtual lectures. Interestingly, the item relevant to discussion time seemed to score the lowest, which may reflect the challenging part of virtual meetings with large audiences. Indeed, many participants suggested increasing the duration of the interaction with the experts in order to improve the quality of the virtual MCOs. Moreover, participants commonly...
Table 2. Distribution of participants by country of origin.

| Country                           | Western Europe (n = 59) | Latin America (n = 42) | Arab countries and southern Europe (n = 32) | Baltic and Eurasia (n = 36) | Eastern Europe and Balkans (n = 31) |
|-----------------------------------|-------------------------|------------------------|--------------------------------------------|-----------------------------|------------------------------------|
| Portugal                          | 19 (32.2%)              | 12 (28.6%)             | 13 (40.6%)                                 | 17 (47.2%)                  | 7 (22.6%)                          |
| ITaly                             | 14 (23.7%)              | 8 (19.0%)              | 5 (15.6%)                                  | 5 (13.8%)                   | 4 (12.9%)                          |
| Belgium                           | 3 (5.1%)                 | 5 (11.9%)              | 4 (12.5%)                                  | 3 (8.3%)                    | 3 (9.7%)                           |
| Sweden                            | 3 (5.1%)                 | 4 (9.5%)               | 2 (6.3%)                                   | 2 (5.6%)                    | 2 (6.5%)                           |
| United Kingdom                    | 3 (5.1%)                 | 4 (9.5%)               | 1 (3.1%)                                   | 2 (5.6%)                    | 2 (6.5%)                           |
| Austria                           | 2 (3.4%)                 | 3 (7.1%)               | 1 (3.1%)                                   | 1 (2.7%)                    | 2 (6.5%)                           |
| France                            | 2 (3.4%)                 | 2 (4.7%)               | 1 (3.1%)                                   | 1 (2.7%)                    | Republic of North Macedonia        |
| Ireland                           | 2 (3.4%)                 | 1 (2.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | Croatia                            |
| Spain                             | 2 (3.4%)                 | 1 (2.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | France                             |
| Finland                           | 1 (1.7%)                 | 1 (2.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | Iran                               |
| Greece                            | 1 (1.7%)                 | 2 (3.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | Italy                              |
| Romania                           | 1 (1.7%)                 | 1 (2.3%)               | 2 (3.3%)                                   | 1 (2.7%)                    | Poland                             |
| Switzerland                       | 1 (1.7%)                 | 1 (2.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | Slovak Republic                    |
| Egypt                             | 1 (1.7%)                 | 1 (2.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | Slovenia                           |
| Lebanon                           | 1 (1.7%)                 | 1 (2.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | Turkey                             |
| Morocco                           | 1 (1.7%)                 | 1 (2.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | 1 (3.2%)                           |
| South Africa                      | 1 (1.7%)                 | 1 (2.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | 1 (3.2%)                           |
| Hong Kong                         | 1 (1.7%)                 | 1 (2.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | 1 (3.2%)                           |
| Australia                         | 1 (1.7%)                 | 1 (2.3%)               | 1 (3.1%)                                   | 1 (2.7%)                    | 1 (3.2%)                           |
Table 3. Evaluation scores$^\dagger$ of the clinical sessions and clinical case presentations by region.

| Clinical session / case presentation | Western Europe | Latin America | Arab countries and southern Europe | Baltic and Eurasia | Eastern Europe and Balkans |
|-------------------------------------|----------------|---------------|-------------------------------------|-------------------|---------------------------|
| Breast cancer                       | 4.77           | 4.85          | 4.66                                | 4.79              | 4.75                      |
| Clinical case discussion            | 4.70           | 4.86          | 4.70                                | 4.82              | 4.79                      |
| Lung cancer                         | 4.70           | 4.75          | 4.54                                | 4.75              | 4.14                      |
| Clinical case discussion            | 4.77           | 4.89          | 4.58                                | 4.84              | 4.86                      |
| Gastrointestinal cancers            | 4.76           | 4.84          | 4.57                                | 4.76              | 4.14                      |
| Clinical case discussion            | 4.78           | 4.90          | 4.71                                | 4.85              | 4.78                      |
| Gynecological cancers               | 4.76           | 4.82          | 4.57                                | 4.81              | 4.72                      |
| Clinical case discussion            | 4.83           | 4.84          | 4.67                                | NA                | 4.90                      |
| Genitourinary cancers               | 4.75           | 4.79          | 4.55                                | 4.78              | 4.74                      |
| Clinical case discussion            | 4.81           | NA            | NA                                  | NA                | 4.88                      |
| Spotlights                          | 4.62           | 4.62          | 4.50                                | 4.77              | 4.69                      |
| Overall                             | 4.75           | 4.81          | 4.60                                | 4.79              | 4.67                      |

$^\dagger$Scores ranged between 1 and 5, with 5 being the highest evaluation.

Table 4. Proportions of participants who responded ‘strongly agree’ or ‘excellent’ in the general, content and organization evaluation sections of the survey.

| Did the e-course offer qualified updates? | Western Europe | Latin America | Arab countries and southern Europe | Baltic and Eurasia | Eastern European and Balkans |
|------------------------------------------|----------------|---------------|-------------------------------------|-------------------|---------------------------|
| Did the e-course improve your skills and your practice? | 83%           | 83%           | 68%                                 | 71%               | 77%                       |
| Give an overall rating for the quality of the e-course. | 85%           | 90%           | 74%                                 | 80%               | 90%                       |
| Was the program well balanced and supported with evidence? | 73%           | 83%           | 58%                                 | 71%               | 77%                       |
| Did the program allow adequate time for discussion? | 51%           | 52%           | 68%                                 | 63%               | 61%                       |
| How would you rate the organization and management of the meeting? | 85%           | 88%           | 81%                                 | 89%               | 87%                       |
| How would you rate the technical system of this e-course? | 71%           | 76%           | 68%                                 | 74%               | 84%                       |

Discuss their queries with the experts after their presentations during in-person events, whereas this accessibility to the experts is not possible during a virtual MCO. The authors attempted to understand the participants’ satisfaction according to their geographic region and detected that the Arab countries and southern Europe MCO had the lowest score for the majority of the items relevant to the goals, content and organization of the meeting. Notably, participants in the Arab countries and southern Europe MCO had the highest proportion of satisfaction with the time dedicated for discussions with the expert panel. This finding underlines a differential need for information among the geographic regions [18–20].

Previous publications have shown that virtual teaching has not been favored over the traditional in-person approach [21–24]. However, these findings cannot be extrapolated to the medical education during the COVID-19 pandemic period, as the workforce was directed toward patient care and teaching activities were suspended. A recent publication reporting on the online education of oncology fellows during the pandemic has shown that most participants felt comfortable with the transition to a fully virtual didactic curriculum [25]. The MCOs occurred during a period with a growing optimism regarding the effectiveness of the COVID-19 vaccine in preventing severe infection and a trend toward involving, at least partly, in-person meetings. Nevertheless, the authors’ experience showed that the virtual ESO-ESMO MCOs achieved higher satisfaction scores in comparison with historical controls from the previous 17 in-person MCOs across the five geographic regions (Figure 1). The survey did not detail the parameters that would influence such improvement because MCOs were originally designed to favor networking and social engagement. The higher differential satisfaction improvements in the western Europe MCOs
followed by the Arab countries and southern Europe MCOs may be attributed to the COVID-19 pandemic surges and cost/convenience benefits, respectively. A satisfaction survey among radiation oncology trainees showed that the reduced cost and travel time were the most common reasons to favor virtual meetings, especially among those training in non-metropolitan centers [26].

Although the current study may be generalizable to the different geographic regions involved, several limitations should be acknowledged. The number of participants in the virtual MCOs was similar to that in the in-person MCOs; nevertheless, the sample size considered for this analysis was quite small. Unfortunately, the authors did not address the survey to the oncologists who had registered for the course but dropped out; however, the concordance of the dropout rate with those of previous years did not allude to particular issues. Finally, this survey may have favored participants with easy access to electronic tools. Participants were not asked specifically about the challenges of the participation modalities, but two issues can be raised. Many participants complained about the short duration of the interaction with the experts and showed lower satisfaction concerning this item of the survey. A minority of the participants found the e-ESO platform complex but quickly adapted to its tools.

### Conclusion & future perspective

The COVID-19 pandemic has accelerated the embrace of modern technologies in academic interactions to maintain continuous medical education, especially during difficult times when expert advice is required. The results of this survey demonstrate that virtual MCOs can be amenable to incorporation into oncology education. This positive feedback from participants from five different geographic regions supports the acceptability of the virtual approach in delivering medical oncology updates. Furthermore, the results of the survey are instructive in directing ESO-ESMO faculty members to adapt the virtual sessions according to the participants’ needs.
Summary points

Introduction
• This study aimed to assess the participants' evaluation of the European School of Oncology–European Society for Medical Oncology virtual masterclasses in clinical oncology (MCOs) organized during the pandemic in 2021.

Methods
• Participants answered an online evaluation questionnaire at the end of each MCO to evaluate the content and organization of the MCO.

Results
• Participants were highly satisfied with virtual MCOs during the COVID-19 pandemic.
• The majority of the participants considered the quality of the meetings to be excellent.
• The Arab countries and southern Europe virtual MCOs had the lowest evaluation.
• The western Europe virtual MCOs had higher improvement in evaluation compared with the in-person events.
• Participants complained mainly of the duration of the interaction with the experts.

Conclusion
• Virtual MCOs may be an acceptable alternative educational modality in specific circumstances.

Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2021-1477

Author contributions
Conceptualization: N Pavlidis; writing – original draft: E Rassy and N Pavlidis; writing – review and editing: all authors; final approval: all authors.

Acknowledgments
The authors would like to thank C Hall, A Ciocchini, D Knupfer and F Marangoni from the European School of Oncology offices for their valuable support. They would also like to thank the participants in the European School of Oncology–European Society for Medical Oncology masterclasses in clinical oncology for answering the surveys.

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research
The authors state that the European School of Oncology ethics board approved the survey and that they have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

References
Papers of special note have been highlighted as: ● of interest; ●● of considerable interest

1. Chua A, Mendora MJ, Ando M et al. Changing the landscape of medical oncology training at the National University Hospital in the Philippines during the coronavirus disease 2019 (COVID-19) pandemic. J. Cancer Educ. 1–3 (2020) (Epub ahead of print).

2. Rana T, Hackett C, Quezada T et al. Medicine and surgery residents’ perspectives on the impact of COVID-19 on graduate medical education. Med. Educ. Online 25(1), 1818439 (2020).

3. Choudhury N, Shoushtari A. Training oncologists in the time of COVID-19. The Oncologist 25(7), 546–547 (2020).

4. Arora R, Mukherjee SD. Strategies for maintaining educational standards in medical oncology residency training in the era of COVID-19: experience from a Canadian cancer centre. J. Cancer Educ. 35(6), 1068–1069 (2020).

5. Banerjee S, Lim KHJ, Murali K et al. The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. ESMO Open 6(2), 100058 (2021).

6. Iyer K, Borok Z. Filling the bench: faculty surge deployment in response to the COVID-19 pandemic. NEJM Catal. Innov. Care Deliv. 1(5) (2020).
7. Shander A, Meroehian J, Weiss J, Javidnooz M. Deploying health care providers during the COVID-19 pandemic. *Disaster Med. Public Health Prep.* 1–4 (2021).

8. European Society for Medical Oncology. COVID-19 and cancer. www.esmo.org/covid-19-and-cancer

9. Gwede CK. The early impact of COVID-19 on cancer education and cancer control. *J. Cancer Educ.* 36(1), 1–2 (2021).

10. Pavlidis N, Gatzemeier W, Popescu R et al. The masterclass of the European School of Oncology: the ‘key educational event’ of the school. *Eur. J. Cancer* 46(12), 2159–2165 (2010).

- **The masterclass in clinical oncology is designed for medical or clinical oncologists who are defining and orientating their professional careers**

11. Pavlidis N, Peccatori FA, Aapro M et al. The impact of the European School of Oncology masterclass in clinical oncology on self-professional development. *Crit. Rev. Oncol. Hematol.* 151, 102976 (2020).

- **The masterclasses in clinical oncology have considerably contributed to trainees’ career development in different oncology disciplines around the world.**

12. Pavlidis N, Peccatori F, Aapro M et al. Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. *Crit. Rev. Oncol. Hematol.* 146, 102798 (2020).

- **The masterclass in clinical oncology is the main educational event of the European School of Oncology. It intends to educate young oncologists from various countries within or outside Europe and provides an up-to-date interactive program based on solid evidence for all presented topics.**

13. Pavlidis N, Khabzarov A, Peccatori FA et al. The contribution of the European School of Oncology Education to the central Asian and Caucasian regions. *J. Cancer Educ.* 37(1), 224–229 (2021).

14. Pavlidis N, Peccatori FA, Aapro M et al. Clinical case presentation and discussion during ESO-ESMO masterclass: a 10-year interactive educational experience. *J. Cancer Educ.* 36(5), 1124–1128 (2020).

- **Clinical case presentation is a unique part of the masterclass in clinical oncology educational program preparing young oncologists to present and discuss their own patients with distinguished experts.**

15. Pavlidis N, Peccatori F, Aapro M et al. ESO-ESMO masterclass in clinical oncology: analysis and evaluation of the learning self-assessment test. *J. Cancer Educ.* 6(3), 556–560 (2021).

- **The major intentions of the learning-self assessment test are the learning reflection of the massive information given during 4–5 days of intensive teaching and to offer the opportunity to participants to prepare themselves for their national boards or for European Society for Medical Oncology examination.**

16. Pavlidis N, Peccatori FA, Eniu A et al. Educational contribution of the College of the European School of Oncology to the Latin American oncologists. *Future Oncol.* 17(23), 2981–2987 (2021).

17. Accreditation Council for Graduate Medical Education. COVID-19: ACGME Response to Pandemic Crisis. https://acgme.org/covid-19/

18. Nicholas P, Mohsen G, Franco C, Alberto C. Euro-Arab School of Oncology: an educational collaborative activity of the European School of Oncology with the Arab world. *J. Cancer Educ.* 26(1), 129–133 (2011).

19. Todorovic V, Aapro M, Pavlidis N et al. AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO-Milan). *J. BUON* 24(5), 2180–2197 (2019).

20. Pavlidis N, Todorovic V, Rassy E et al. The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey. *Future Oncol.* 17(2), 151–157 (2021).

21. Ruiz JG, Mintzer MJ, Leipzig RM. The impact of e-learning in medical education. *Acad. Med.* 81(3), 207–212 (2006).

22. Harris JM, Sklar BM, Amend RW, Novalis-Marine C. The growth, characteristics, and future of online CME. *J. Contin. Educ. Health Prof.* 30(1), 3–10 (2010).

23. Young KJ, Kim JJ, Yeung G, Sit C, Tohe SW. Physician preferences for accredited online continuing medical education. *J. Contin. Educ. Health Prof.* 31(4), 241–246 (2011).

24. Cragun D, Besharat AD, Lewis C, Vadaparampil ST, Pal T. Educational needs and preferred methods of learning among Florida practitioners who order genetic testing for hereditary breast and ovarian cancer. *J. Cancer Educ.* 28(4), 690–697 (2013).

25. Singh EK, Dupuis MM, Ross JA, Rieber AG, Bhadkamkar NA. Medical hematology/oncology fellows’ perceptions of online medical education during the COVID-19 pandemic. *J. Cancer Educ.* 35(5), 1034–1040 (2020).

26. Turner S, Pham T, Robledo K, Turner S, Brown C, Sundaresan P. Rapid adaptation of cancer education in response to the COVID-19 pandemic: evaluation of a live virtual statistics and research skills workshop for oncology trainees. *J. Cancer Educ.* 1–6 (2020) (Epub ahead of print).